|Description||[18F]RPS-041 is a novel labeled PSMA ligand which can be used for detection of prostate cancer by positron emission tomography (PET).|
|Brife Description||PSMA ligand, detection of prostate cancer|
|Application||detection of prostate cancer|
|Current Developer||Weill Cornell Medicine|
Topocecan is a semisynthetic derivative of camptothecin with antineoplastic activity. During the S phase of the cell cycle, topotecan selectively stabilizes top...
BAY-386 is a novel PAR1 receptor inhibitor that suppresses activation of thrombin and platelet. It is orally active, and has the potential to treat coagulation ...
CGP-79807 is a potent CDC2 protein kinase inhibitor that originated by Novartis. In Sep 2000, Preclinical development for Cancer in Switzerland was on-going, bu...
CMK is a RSK2 kinase inhibitor. Its IC50 value for Cdc5(L158G) is 36 nM. It is used in the preparation of serine/threonine kinase inhibitors.
EUK 134, a synthetic superoxide dismutase (SOD)/catalase mimetic, exhibits potent antioxidant activities, and inhibits the formation of β-amyloid and related am...
Ivacaftor is a potentiator of CFTR targeting G551D-CFTR(EC50=100 nM)and F508del-CFTR(EC50=25 nM).
A 779 is a specific antagonist of G-protein coupled receptor (Mas receptor) (IC50= 0.3 nM) with no significant affinity for AT1 or AT2 receptors at a concentrat...
A small-molecule agonist of TLR7